Effect of Periodontitis on the Quality and Quantity of Leukocyte- and Platelet-Rich Fibrin (L-PRF)

Periodontitis is a chronic inflammatory disease that destroys the supporting tissues of the teeth and may also increase systemic inflammatory burden. Leukocyte- and platelet-rich fibrin (L-PRF) is an autologous blood-derived biomaterial widely used in periodontal and oral regenerative procedures because it contains platelets, leukocytes, growth factors, and a fibrin matrix that promotes wound healing and tissue regeneration. The purpose of this study is to determine whether Stage III-IV generalized periodontitis affects the quality and quantity of L-PRF. L-PRF obtained from periodontally healthy individuals and patients with generalized Stage III-IV periodontitis will be compared by evaluating fibrin architecture, cellular composition, and the temporal release of growth factors. The findings are expected to improve understanding of whether systemic inflammatory changes associated with periodontitis influence the biological properties of L-PRF and its regenerative potential.

Inclusion Criteria: * Diagnosed as periodontally healthy or Stage III-IV generalized periodontitis according to the 2017 World Workshop Classification. * Adults aged 30-50 years. * Systemically healthy individuals. * Non-smokers. * Referred from the Department of Oral and Maxillofacial Radiology to the Department of Periodontology due to periodontal disease. * Willing and able to provide written informed consent and participate in the study. Exclusion Criteria: * Refusal or inability to provide informed consent or participate in the study. * Presence of any systemic disease. * Current smokers. * Pregnancy or breastfeeding. * Individuals with physical or psychological disabilities that may interfere with study participation. * History of substance abuse. * Severe malocclusion. * Current orthodontic treatment, use of orthodontic appliances, or removable prostheses. * Presence of acute dental pain or infection (e.g., dental caries, abscess, or acute odontogenic infection). * History or presence of malignant disease. * Participation in another clinical study at the time of enrollment.